CHIR 98014

Grouped product items
SizePrice Qty
Catalog Number : 5563993


CHIR 98014 is a potent and reversible inhibitor of Glycogen Synthase Kinase 3 (GSK3), inhibiting both the alpha (IC50: 0.65 nM) and beta (IC50: 0.58 nM) isoforms. GSK3 functions by phosphorylating a serine or threonine residue on its target substrate and is part of the Wnt pathway that signals the cell to divide and proliferate. CHIR 98014 activates glycogen synthase in cells to improve glucose disposal and to reduce tau phosphorylation in neurons. It is reported to stimulate vascular cell differentiation of hPSC and enhances the transformation of vascular smooth muscle cells into osteogenic-like cells under high phosphate conditions.

Additional Information

CHIR98014, CHIR-98014
Crystalline solid
Chemical Name:
Molecular Formula:


Molecular Weight:
CAS Number
Storage Conditions:
Product should be kept at -20°C.

Ring, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., ... & Wagman, A. S. (2003). Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes52(3), 588-595.

Naujok, O., Lentes, J., Diekmann, U., Davenport, C., & Lenzen, S. (2014). Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC research notes7(1), 1.

Lian, X., Bao, X., Al-Ahmad, A., Liu, J., Wu, Y., Dong, W., ... & Palecek, S. P. (2014). Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling. Stem cell reports3(5), 804-816.

Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., ... & Palecek, S. P. (2012). Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling.Proceedings of the National Academy of Sciences109(27), E1848-E1857.

© BioGems International, Inc. All rights reserved.